The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 trial results of DN24-02, a HER2-targeted autologous cellular immunotherapy in HER2+ urothelial cancer patients (pts).
 
Dean F. Bajorin
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Fidia Farmaceutici S. p. A.; Genentech; Lilly; Merck; Novartis; Roche; Roche/Genentech
Research Funding - Amgen (Inst); dendreon (Inst); Genentech/Roche (Inst); Merck; Novartis (Inst)
Travel, Accommodations, Expenses - Merck; Roche/Genentech
 
Padmanee Sharma
Stock and Other Ownership Interests - Jounce Therapeutics; Kite, a Gilead company
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Jounce Therapeutics; Kite, a Gilead company
 
David I. Quinn
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Dendreon; Fresenius Kabi; Genentech/Roche; Janssen Oncology; Medivation; Novartis; Pfizer
Consulting or Advisory Role - Algeta/Bayer; Astellas Pharma; Bristol-Myers Squibb; Dendreon; Genentech/Roche; Janssen Oncology; Medivation; Novartis; Pfizer
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Sanofi (Inst)
Expert Testimony - Medivation; Teva
 
Elizabeth R. Plimack
Consulting or Advisory Role - Acceleron Pharma; Bristol-Myers Squibb; Dendreon; Genentech/Roche; GlaxoSmithKline; Merck; Novartis; Pfizer
Research Funding - Acceleron Pharma (Inst); Acerta Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst)
 
Jean H. Hoffman-Censits
Honoraria - Roche/Genentech
Consulting or Advisory Role - Roche/Genentech
Research Funding - Sanofi
Travel, Accommodations, Expenses - Roche/Genentech
 
Peter H. O'Donnell
Stock and Other Ownership Interests - Davita
Honoraria - Algeta ASA; Dendreon; OptumHealth
Research Funding - Boehringer Ingelheim (Inst)
Patents, Royalties, Other Intellectual Property - Named as co-inventor on a pending patent for a genomic prescribing system for medication prescribing.
Travel, Accommodations, Expenses - Sequenom
 
Arlene O. Siefker-Radtke
Consulting or Advisory Role - Janssen; Merck; NCCN; Threshold Pharmaceuticals
Research Funding - Genentech; Michael and Sherry Sutton Fund for Urothelial Cancer; Millennium; NIH
Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.
 
Nadeem Anwar Sheikh
Employment - Dendreon
Stock and Other Ownership Interests - Valeant Pharmaceuticals International
Patents, Royalties, Other Intellectual Property - Valeant/Dendreon
 
Jennifer Susan LIll
Employment - Dendreon
Stock and Other Ownership Interests - Bristol-Myers Squibb; Valeant Pharmaceuticals International
 
James B. Trager
Employment - Dendreon
Stock and Other Ownership Interests - Valeant Pharmaceuticals International
Patents, Royalties, Other Intellectual Property - Valeant/Dendreon
 
Leonard G. Gomella
Consulting or Advisory Role - Bayer; Dendreon; Janssen; MDxHealth; Tolmar
Research Funding - Astellas Pharma; FdK; Janssen
Patents, Royalties, Other Intellectual Property - Self